NASDAQ · RVMD
Revolution Medicines, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RVMD: Nov 04, 2026
Revolution Medicines, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 11 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.34. The reported EPS for the same quarter last year was $-1.61.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.34 | $-2.07 | $-2.50 | 11 |
| Dec 2026 | $-2.14 | $-1.12 | $-3.02 | 11 |
| Mar 2027 | $-1.78 | $-1.07 | $-2.10 | 8 |
| Jun 2027 | $-1.80 | $-0.88 | $-2.28 | 8 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · RTTNews · Fintel- The Motley Fool · Oct 29, 5:04 AM EDTCould Revolution Medicines Be a Millionaire-Maker Stock?Revolution Medicines' stock has soared over 9x in three years.
- The Motley Fool · Oct 27, 6:01 PM EDTBillionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?Stanley Druckenmiller’s Duquesne Family Office increased its stake in Revolution Medicines during the second quarter.
- RTTNews · Oct 23, 8:30 AM EDTRVMD's RASONQUE Shows Survival Benefit Across Key Patient Group In Metastatic Pancreatic Cancer(RTTNews) – Revolution Medicines, Inc. (RVMD) presented new subgroup analyses from its Phase 3 RASolute 302 trial showing that RASONQUE (daraxonrasib) continued to deliver an overall survival benefit compared with chemotherapy across multiple patient groups with previously treate
- RTTNews · Oct 20, 2:49 PM EDTBiotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40%(RTTNews) – Correction: The earlier fact provided in "This Day in History" was incorrect. It has been updated with the correct information.
- RTTNews · Oct 20, 11:10 AM EDTRevolution Medicines Begins Phase 3 Trial Of Three-Drug Lung Cancer Regimen; Stock Up(RTTNews) – Revolution Medicines, Inc. (RVMD), an oncology company focused on RAS-driven cancers, announced that it has begun treating patients in the Phase 3 RASolve 308 trial evaluating investigational zoldonrasib in combination with pembrolizumab and chemotherapy as a first-li
- Fintel · Oct 16, 9:06 PM EDTWilliam Blair Initiates Coverage of Revolution Medicines at OutperformFintel reports that on October 16, 2026, William Blair initiated coverage of Revolution Medicines (NASDAQGS:RVMD) (BIT:1RVMD) with a Outperform recommendation.Revolution Medicines, Inc., based in the United States, operates within the biotechnology industry, specifically focusing
- The Motley Fool · Oct 15, 3:34 PM EDTThese 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside AheadRevolution Medicines recently made a breakthrough in oncology.
- RTTNews · Oct 15, 1:28 PM EDTRevolution Medicines' Pancreatic Cancer Drug Gets Positive EU Review(RTTNews) – Revolution Medicines (RVMD) on Thursday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for RASONQUE (daraxonrasib) to treat adults with metastatic pancreatic adenocarcinoma who have re
- The Motley Fool · Sep 24, 10:35 PM EDTIs Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer.
- The Motley Fool · Sep 18, 9:00 AM EDTAxsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments.
- The Motley Fool · Sep 17, 4:20 AM EDTRevolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?Revolution Medicines validated its approach to treating certain cancers with a recent regulatory approval.
- RTTNews · Sep 15, 2:16 AM EDTRevolution Medicines' Daraxonrasib Secures FDA Breakthrough Designation In Pancreatic Cancer(RTTNews) – Revolution Medicines, Inc. (RVMD), a commercial-stage oncology company developing medicines for RAS-addicted cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), a RAS(ON) multi-se
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Revolution Medicines, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.